ProCE Banner Activity

Interpreting COVID-19 Data From IDWeek 2022: Prophylaxis, Treatment, and Opportunistic Infections in Immunocompromised Individuals

Clinical Thought

COVID-19 continued to be a major focus at IDWeek 2022, with research investigating many facets of infection, including 4 studies that I found particularly interesting—analyses of baricitinib or tocilizumab for severe COVID-19, inhaled interferon beta-1a for moderate COVID-19, and tixagevimab plus cilgavimab for pre-exposure prophylaxis in immunocompromised individuals, and outcomes among adult solid organ transplant recipients with COVID-19–associated fungal infections.

Released: November 17, 2022

Share

Faculty

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, GlaxoSmithKline, Janssen, MSD, Pfizer, Roche, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.